As chordomas are consistently referred to as chemoresistant, novel molecular targets are sought [45,60], which include the platelet-derived growth factor receptors (PDGFRs) targeted by imatinib and dasatinib; epidermal growth factor receptor (EGFR), targeted by erlotinib, lapatinib, gefitinib, and cetuximab; and vascular endothelial growth factor receptor (VEGFR), targeted by antiangiogenics such as sorafenib, pazopanib, and sunitinib. Here, EGFR is linked to chordoma.